A study funded by the National Institutes of Health has found that adults who were hospitalized for a severe infection, such ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to assess ...

The study is being sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institute of Health (NIH). Fostamatinib, marketed in the U.S. as TAVALISSE ...

One of CTRID's strategic objectives is to enhance the training of basic and clinical researchers. Our NIH/NHLBI T32 training grant entitled “Collaborative Research Training in Thrombosis and ...

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.

CLM reports grant funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). She is a consultant for the nonprofit Biologics and Biosimilars Collective ...

NIH funded study finds infection-related hospitalizations linked to increased risk of heart failure: Bethesda, Maryland Thursday, February 13, 2025, 18:00 Hrs [IST] A study funded ...